Fri Jul 24, 2009 - 6:00pm EDT - Reuters* Biogen reports 11th case of Tysabri brain infection
* Tysabri seen as key growth driver for Biogen
* Company says won't report new cases on website
BOSTON, July 24 (Reuters) - An 11th patient taking Biogen
Idec Inc's ( BIIB.O ) multiple sclerosis drug Tysabri has
developed a potentially deadly brain infection since July 2006,
when it was reintroduced to the market.
The Cambridge, Massachusetts-based biotech company released
the news on its website late on Friday.
Tysabri, which Biogen sells in conjunction with Irish
drugmaker Elan Corp Plc ( ELN.I ), is considered critical to the
future growth of both companies.
Click hereto continue reading this Reuters report
============================================
============================================